2xah › Citations

Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.

Binda C, Valente S, Romanenghi M, Pilotto S, Cirilli R, Karytinos A, Ciossani G, Botrugno OA, Forneris F, Tardugno M, Edmondson DE, Minucci S, Mattevi A, Mai A
J Am Chem Soc 132 6827-33 (2010)
Related entries: 2xaf, 2xag, 2xaj, 2xaq, 2xas

Cited: 144 times
EuropePMC logo PMID: 20415477

Abstract

LSD1 and LSD2 histone demethylases are implicated in a number of physiological and pathological processes, ranging from tumorigenesis to herpes virus infection. A comprehensive structural, biochemical, and cellular study is presented here to probe the potential of these enzymes for epigenetic therapies. This approach employs tranylcypromine as a chemical scaffold for the design of novel demethylase inhibitors. This drug is a clinically validated antidepressant known to target monoamine oxidases A and B. These two flavoenzymes are structurally related to LSD1 and LSD2. Mechanistic and crystallographic studies of tranylcypromine inhibition reveal a lack of selectivity and differing covalent modifications of the FAD cofactor depending on the enantiomeric form. These findings are pharmacologically relevant, since tranylcypromine is currently administered as a racemic mixture. A large set of tranylcypromine analogues were synthesized and screened for inhibitory activities. We found that the common evolutionary origin of LSD and MAO enzymes, despite their unrelated functions and substrate specificities, is reflected in related ligand-binding properties. A few compounds with partial enzyme selectivity were identified. The biological activity of one of these new inhibitors was evaluated with a cellular model of acute promyelocytic leukemia chosen since its pathogenesis includes aberrant activities of several chromatin modifiers. Marked effects on cell differentiation and an unprecedented synergistic activity with antileukemia drugs were observed. These data demonstrate that these LSD1/2 inhibitors are of potential relevance for the treatment of promyelocytic leukemia and, more generally, as tools to alter chromatin state with promise of a block of tumor progression.

Reviews - 2xah mentioned but not cited (5)

  1. Inhibitors of Protein Methyltransferases and Demethylases. Kaniskan HÜ, Martini ML, Jin J. Chem Rev 118 989-1068 (2018)
  2. Targeting histone lysine demethylases - progress, challenges, and the future. Thinnes CC, England KS, Kawamura A, Chowdhury R, Schofield CJ, Hopkinson RJ. Biochim Biophys Acta 1839 1416-1432 (2014)
  3. The role of histone demethylases in cancer therapy. Hoffmann I, Roatsch M, Schmitt ML, Carlino L, Pippel M, Sippl W, Jung M. Mol Oncol 6 683-703 (2012)
  4. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Andreoli F, Barbosa AJ, Parenti MD, Del Rio A. Curr Pharm Des 19 578-613 (2013)
  5. Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases. Niwa H, Umehara T. Epigenetics 12 340-352 (2017)

Articles - 2xah mentioned but not cited (1)

  1. Coordinated methyl-lysine erasure: structural and functional linkage of a Jumonji demethylase domain and a reader domain. Upadhyay AK, Horton JR, Zhang X, Cheng X. Curr Opin Struct Biol 21 750-760 (2011)


Reviews citing this publication (63)

  1. Epigenetic protein families: a new frontier for drug discovery. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Nat Rev Drug Discov 11 384-400 (2012)
  2. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Morera L, Lübbert M, Jung M. Clin Epigenetics 8 57 (2016)
  3. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Abdel-Wahab O, Levine RL. Blood 121 3563-3572 (2013)
  4. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. Fang Y, Liao G, Yu B, Yu B. J Hematol Oncol 12 129 (2019)
  5. The histone LSD1 demethylase in stemness and cancer transcription programs. Amente S, Lania L, Majello B. Biochim Biophys Acta 1829 981-986 (2013)
  6. Structural insights into histone lysine demethylation. Hou H, Yu H. Curr Opin Struct Biol 20 739-748 (2010)
  7. Targeting histone lysine methylation in cancer. McGrath J, Trojer P. Pharmacol Ther 150 1-22 (2015)
  8. LSD1: biologic roles and therapeutic targeting. Maiques-Diaz A, Somervaille TC. Epigenomics 8 1103-1116 (2016)
  9. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors. Zheng YC, Ma J, Wang Z, Li J, Jiang B, Zhou W, Shi X, Wang X, Zhao W, Liu HM. Med Res Rev 35 1032-1071 (2015)
  10. The winding path of protein methylation research: milestones and new frontiers. Murn J, Shi Y. Nat Rev Mol Cell Biol 18 517-527 (2017)
  11. Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. Song Y, Wu F, Wu J. J Hematol Oncol 9 49 (2016)
  12. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Hosseini A, Minucci S. Epigenomics 9 1123-1142 (2017)
  13. Epigenomics of leukemia: from mechanisms to therapeutic applications. Florean C, Schnekenburger M, Grandjenette C, Dicato M, Diederich M. Epigenomics 3 581-609 (2011)
  14. LSD1 inhibition: a therapeutic strategy in cancer? Lynch JT, Harris WJ, Somervaille TC. Expert Opin Ther Targets 16 1239-1249 (2012)
  15. Current status and future prospects for epigenetic psychopharmacology. Boks MP, de Jong NM, Kas MJ, Vinkers CH, Fernandes C, Kahn RS, Mill J, Ophoff RA. Epigenetics 7 20-28 (2012)
  16. Inhibitors of histone demethylases. Lohse B, Kristensen JL, Kristensen LH, Agger K, Helin K, Gajhede M, Clausen RP. Bioorg Med Chem 19 3625-3636 (2011)
  17. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs. Ramsay RR, Tipton KF. Molecules 22 E1192 (2017)
  18. Advances toward LSD1 inhibitors for cancer therapy. Fu X, Zhang P, Yu B. Future Med Chem 9 1227-1242 (2017)
  19. Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance. Cho Y, Kim YK. Front Oncol 10 764 (2020)
  20. A chemical probe toolbox for dissecting the cancer epigenome. Shortt J, Ott CJ, Johnstone RW, Bradner JE. Nat Rev Cancer 17 160-183 (2017)
  21. Targeting protein lysine methylation and demethylation in cancers. He Y, Korboukh I, Jin J, Huang J. Acta Biochim Biophys Sin (Shanghai) 44 70-79 (2012)
  22. Flavins as Covalent Catalysts: New Mechanisms Emerge. Piano V, Palfey BA, Mattevi A. Trends Biochem Sci 42 457-469 (2017)
  23. Epigenetic polypharmacology: A new frontier for epi-drug discovery. Tomaselli D, Lucidi A, Rotili D, Mai A. Med Res Rev 40 190-244 (2020)
  24. KDM1 class flavin-dependent protein lysine demethylases. Burg JM, Link JE, Morgan BS, Heller FJ, Hargrove AE, McCafferty DG. Biopolymers 104 213-246 (2015)
  25. Kinetics, mechanism, and inhibition of monoamine oxidase. Ramsay RR, Albreht A. J Neural Transm (Vienna) 125 1659-1683 (2018)
  26. KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. Maes T, Mascaró C, Ortega A, Lunardi S, Ciceri F, Somervaille TC, Buesa C. Epigenomics 7 609-626 (2015)
  27. Targeting epigenetic regulators to overcome drug resistance in cancers. Wang N, Ma T, Yu B, Yu B. Signal Transduct Target Ther 8 69 (2023)
  28. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy. Zheng YC, Yu B, Chen ZS, Liu Y, Liu HM. Epigenomics 8 651-666 (2016)
  29. Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. Ramsay RR, Majekova M, Medina M, Valoti M. Front Neurosci 10 375 (2016)
  30. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs. Gelato KA, Adler D, Ocker M, Haendler B. Expert Opin Ther Targets 20 783-799 (2016)
  31. Epigenetics: A primer for clinicians. Paluch BE, Naqash AR, Brumberger Z, Nemeth MJ, Griffiths EA. Blood Rev 30 285-295 (2016)
  32. Histone Lysine Demethylase Inhibitors. Jambhekar A, Anastas JN, Shi Y. Cold Spring Harb Perspect Med 7 a026484 (2017)
  33. The role of chromatin repressive marks in cognition and disease: A focus on the repressive complex GLP/G9a. Benevento M, van de Molengraft M, van Westen R, van Bokhoven H, Kasri NN. Neurobiol Learn Mem 124 88-96 (2015)
  34. Tranylcypromine in mind (Part I): Review of pharmacology. Ulrich S, Ricken R, Adli M. Eur Neuropsychopharmacol 27 697-713 (2017)
  35. Epigenetic gene regulation by histone demethylases: emerging role in oncogenesis and inflammation. Kang MK, Mehrazarin S, Park NH, Wang CY. Oral Dis 23 709-720 (2017)
  36. Small-molecular modulators of cancer-associated epigenetic mechanisms. Itoh Y, Suzuki T, Miyata N. Mol Biosyst 9 873-896 (2013)
  37. Targeting histone methylation for colorectal cancer. Huang T, Lin C, Zhong LL, Zhao L, Zhang G, Lu A, Wu J, Bian Z. Therap Adv Gastroenterol 10 114-131 (2017)
  38. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases. Wang Z, Patel DJ. Q Rev Biophys 46 349-373 (2013)
  39. Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. Franci G, Miceli M, Altucci L. Epigenomics 2 731-742 (2010)
  40. LSD1 Histone Demethylase Assays and Inhibition. Hayward D, Cole PA. Methods Enzymol 573 261-278 (2016)
  41. An overview of phenylcyclopropylamine derivatives: biochemical and biological significance and recent developments. Khan MN, Suzuki T, Miyata N. Med Res Rev 33 873-910 (2013)
  42. The growing structural and functional complexity of the LSD1/KDM1A histone demethylase. Marabelli C, Marrocco B, Mattevi A. Curr Opin Struct Biol 41 135-144 (2016)
  43. Using zebrafish as a model to study the role of epigenetics in hearing loss. He Y, Bao B, Li H. Expert Opin Drug Discov 12 967-975 (2017)
  44. Flavin-dependent enzymes in cancer prevention. Wojcieszyńska D, Hupert-Kocurek K, Guzik U. Int J Mol Sci 13 16751-16768 (2012)
  45. High-throughput screening for genes that prevent excess DNA replication in human cells and for molecules that inhibit them. Lee CY, Johnson RL, Wichterman-Kouznetsova J, Guha R, Ferrer M, Tuzmen P, Martin SE, Zhu W, DePamphilis ML. Methods 57 234-248 (2012)
  46. Monoamine oxidase A and B substrates: probing the pathway for drug development. Chajkowski-Scarry S, Rimoldi JM. Future Med Chem 6 697-717 (2014)
  47. Bioactive food components, cancer cell growth limitation and reversal of glycolytic metabolism. Keijer J, Bekkenkamp-Grovenstein M, Venema D, Dommels YE. Biochim Biophys Acta 1807 697-706 (2011)
  48. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview. Eglen RM, Reisine T. J Biomol Screen 16 1137-1152 (2011)
  49. The structure of monoamine oxidases: past, present, and future. Iacovino LG, Magnani F, Binda C. J Neural Transm (Vienna) 125 1567-1579 (2018)
  50. Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation. Perner F, Armstrong SA. Cells 9 E2721 (2020)
  51. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials. Noce B, Di Bello E, Fioravanti R, Mai A. Front Pharmacol 14 1120911 (2023)
  52. Toward development of epigenetic drugs for central nervous system disorders: Modulating neuroplasticity via H3K4 methylation. Ricq EL, Hooker JM, Haggarty SJ. Psychiatry Clin Neurosci 70 536-550 (2016)
  53. Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia. San Jose-Eneriz E, Agirre X, Rodríguez-Otero P, Prosper F. Epigenomics 5 525-538 (2013)
  54. Histone methylation in myelodysplastic syndromes. Wei Y, Gañán-Gómez I, Salazar-Dimicoli S, McCay SL, Garcia-Manero G. Epigenomics 3 193-205 (2011)
  55. Synthetic applications of hypophosphite derivatives in reduction. Guyon C, Métay E, Popowycz F, Lemaire M. Org Biomol Chem 13 7879-7906 (2015)
  56. Epigenetic molecular recognition: a biomolecular modeling perspective. Vellore NA, Baron R. ChemMedChem 9 484-494 (2014)
  57. Histone demethylases in the regulation of immunity and inflammation. Qu L, Yin T, Zhao Y, Lv W, Liu Z, Chen C, Liu K, Shan S, Zhou R, Li X, Dong H. Cell Death Discov 9 188 (2023)
  58. LSD1: a viable therapeutic target in cutaneous squamous cell carcinoma? Egolf S, Capell BC. Expert Opin Ther Targets 24 671-678 (2020)
  59. Biological and therapeutic role of LSD1 in Alzheimer's diseases. Li Y, Zhao Y, Li X, Zhai L, Zheng H, Yan Y, Fu Q, Ma J, Fu H, Zhang Z, Li Z. Front Pharmacol 13 1020556 (2022)
  60. Chemical Inhibitors Targeting the Histone Lysine Demethylase Families with Potential for Drug Discovery. Das ND, Niwa H, Umehara T. Epigenomes 7 7 (2023)
  61. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks. Stitzlein LM, Adams JT, Stitzlein EN, Dudley RW, Chandra J. J Exp Clin Cancer Res 43 12 (2024)
  62. Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer. Beljkas M, Ilic A, Cebzan A, Radovic B, Djokovic N, Ruzic D, Nikolic K, Oljacic S. Pharmaceutics 15 2581 (2023)
  63. Targeting the LSD1/KDM1 Family of Lysine Demethylases in Cancer and Other Human Diseases. Mao F, Shi YG. Adv Exp Med Biol 1433 15-49 (2023)

Articles citing this publication (75)

  1. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA, Marton L, Woster P, Minden MD, Dugas M, Wang JC, Dick JE, Müller-Tidow C, Petrie K, Zelent A. Nat Med 18 605-611 (2012)
  2. Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Rotili D, Mai A. Genes Cancer 2 663-679 (2011)
  3. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. Nat Commun 9 53 (2018)
  4. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Singh MM, Manton CA, Bhat KP, Tsai WW, Aldape K, Barton MC, Chandra J. Neuro Oncol 13 894-903 (2011)
  5. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. Zheng YC, Duan YC, Ma JL, Xu RM, Zi X, Lv WL, Wang MM, Ye XW, Zhu S, Mobley D, Zhu YY, Wang JW, Li JF, Wang ZR, Zhao W, Liu HM. J Med Chem 56 8543-8560 (2013)
  6. Brain-penetrant LSD1 inhibitors can block memory consolidation. Neelamegam R, Ricq EL, Malvaez M, Patnaik D, Norton S, Carlin SM, Hill IT, Wood MA, Haggarty SJ, Hooker JM. ACS Chem Neurosci 3 120-128 (2012)
  7. Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). Sakane N, Kwon HS, Pagans S, Kaehlcke K, Mizusawa Y, Kamada M, Lassen KG, Chan J, Greene WC, Schnoelzer M, Ott M. PLoS Pathog 7 e1002184 (2011)
  8. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, Persson JL, Gudas LJ, Mongan NP. Mol Oncol 7 555-566 (2013)
  9. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. Sharma SK, Wu Y, Steinbergs N, Crowley ML, Hanson AS, Casero RA, Woster PM. J Med Chem 53 5197-5212 (2010)
  10. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei L, Liu W, Dong S, Redell M, Mo Q, Song Y. J Hematol Oncol 9 24 (2016)
  11. A selective phenelzine analogue inhibitor of histone demethylase LSD1. Prusevich P, Kalin JH, Ming SA, Basso M, Givens J, Li X, Li X, Hu J, Taylor MS, Taylor MS, Cieniewicz AM, Hsiao PY, Huang R, Roberson H, Adejola N, Avery LB, Casero RA, Taverna SD, Qian J, Tackett AJ, Ratan RR, McDonald OG, Feinberg AP, Cole PA. ACS Chem Biol 9 1284-1293 (2014)
  12. Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and -independent manners. Pollock JA, Larrea MD, Jasper JS, McDonnell DP, McCafferty DG. ACS Chem Biol 7 1221-1231 (2012)
  13. LSD2/KDM1B and its cofactor NPAC/GLYR1 endow a structural and molecular model for regulation of H3K4 demethylation. Fang R, Chen F, Dong Z, Hu D, Barbera AJ, Clark EA, Fang J, Yang Y, Mei P, Rutenberg M, Li Z, Zhang Y, Xu Y, Yang H, Wang P, Simon MD, Zhou Q, Li J, Marynick MP, Li X, Lu H, Kaiser UB, Kingston RE, Xu Y, Shi YG. Mol Cell 49 558-570 (2013)
  14. Novel 3,5-bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors: enzyme selectivity and cellular activity. Cheng D, Valente S, Castellano S, Sbardella G, Di Santo R, Costi R, Bedford MT, Mai A. J Med Chem 54 4928-4932 (2011)
  15. The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. Milczek EM, Binda C, Rovida S, Mattevi A, Edmondson DE. FEBS J 278 4860-4869 (2011)
  16. Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer. Tan AHY, Tu W, McCuaig R, Hardy K, Donovan T, Tsimbalyuk S, Forwood JK, Rao S. Front Immunol 10 1351 (2019)
  17. NMDA receptor- and ERK-dependent histone methylation changes in the lateral amygdala bidirectionally regulate fear memory formation. Gupta-Agarwal S, Jarome TJ, Fernandez J, Lubin FD. Learn Mem 21 351-362 (2014)
  18. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation. Ravasio R, Ceccacci E, Nicosia L, Hosseini A, Rossi PL, Barozzi I, Fornasari L, Zuffo RD, Valente S, Fioravanti R, Mercurio C, Varasi M, Mattevi A, Mai A, Pavesi G, Bonaldi T, Minucci S. Sci Adv 6 eaax2746 (2020)
  19. Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. Binda C, Aldeco M, Geldenhuys WJ, Tortorici M, Mattevi A, Edmondson DE. ACS Med Chem Lett 3 39-42 (2011)
  20. 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1. Wu F, Zhou C, Yao Y, Wei L, Feng Z, Deng L, Song Y. J Med Chem 59 253-263 (2016)
  21. Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1. Hazeldine S, Pachaiyappan B, Steinbergs N, Nowotarski S, Hanson AS, Casero RA, Woster PM. J Med Chem 55 7378-7391 (2012)
  22. Lysine-specific demethylase 1-selective inactivators: protein-targeted drug delivery mechanism. Ogasawara D, Itoh Y, Tsumoto H, Kakizawa T, Mino K, Fukuhara K, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N, Suzuki T. Angew Chem Int Ed Engl 52 8620-8624 (2013)
  23. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. Barth J, Abou-El-Ardat K, Dalic D, Kurrle N, Maier AM, Mohr S, Schütte J, Vassen L, Greve G, Schulz-Fincke J, Schmitt M, Tosic M, Metzger E, Bug G, Khandanpour C, Wagner SA, Lübbert M, Jung M, Serve H, Schüle R, Berg T. Leukemia 33 1411-1426 (2019)
  24. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity. Schmitt ML, Hauser AT, Carlino L, Pippel M, Schulz-Fincke J, Metzger E, Willmann D, Yiu T, Barton M, Schüle R, Sippl W, Jung M. J Med Chem 56 7334-7342 (2013)
  25. Azalysine analogues as probes for protein lysine deacetylation and demethylation. Dancy BC, Ming SA, Papazyan R, Jelinek CA, Majumdar A, Sun Y, Dancy BM, Drury WJ, Cotter RJ, Taverna SD, Cole PA. J Am Chem Soc 134 5138-5148 (2012)
  26. Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features. Speranzini V, Rotili D, Ciossani G, Pilotto S, Marrocco B, Forgione M, Lucidi A, Forneris F, Mehdipour P, Velankar S, Mai A, Mattevi A. Sci Adv 2 e1601017 (2016)
  27. Inhibition of H3K4me2 Demethylation Protects Auditory Hair Cells from Neomycin-Induced Apoptosis. He Y, Yu H, Cai C, Sun S, Chai R, Li H. Mol Neurobiol 52 196-205 (2015)
  28. Thermodynamic characterization of the binding interaction between the histone demethylase LSD1/KDM1 and CoREST. Hwang S, Schmitt AA, Luteran AE, Toone EJ, McCafferty DG. Biochemistry 50 546-557 (2011)
  29. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia. Deb G, Wingelhofer B, Amaral FMR, Maiques-Diaz A, Chadwick JA, Spencer GJ, Williams EL, Leong HS, Maes T, Somervaille TCP. Leukemia 34 1266-1277 (2020)
  30. A reversible fluorescent probe based on C[double bond, length as m-dash]N isomerization for the selective detection of formaldehyde in living cells and in vivo. Song X, Han X, Yu F, Zhang J, Chen L, Lv C. Analyst 143 429-439 (2018)
  31. Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient. Doll S, Kriegmair MC, Santos A, Wierer M, Coscia F, Neil HM, Porubsky S, Geyer PE, Mund A, Nuhn P, Mann M. Mol Oncol 12 1296-1307 (2018)
  32. Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives. Sakane C, Okitsu T, Wada A, Sagami H, Shidoji Y. Biochem Biophys Res Commun 444 24-29 (2014)
  33. Overexpression of lysine-specific demethylase 1 in ovarian endometriomas and its inhibition reduces cellular proliferation, cell cycle progression, and invasiveness. Ding D, Liu X, Guo SW. Fertil Steril 101 740-749 (2014)
  34. cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases. Malcomson T, Yelekci K, Borrello MT, Ganesan A, Semina E, De Kimpe N, Mangelinckx S, Ramsay RR. FEBS J 282 3190-3198 (2015)
  35. Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma. Liu YD, Dai M, Yang SS, Xiao M, Meng FL, Chen XW. Int J Gynecol Cancer 25 1453-1460 (2015)
  36. Serotonin Transporter Gene Promoter Hypomethylation as a Predictor of Antidepressant Treatment Response in Major Depression: A Replication Study. Schiele MA, Zwanzger P, Schwarte K, Arolt V, Baune BT, Domschke K. Int J Neuropsychopharmacol 24 191-199 (2021)
  37. Epigenetic control and cancer: the potential of histone demethylases as therapeutic targets. Lizcano F, Garcia J. Pharmaceuticals (Basel) 5 963-990 (2012)
  38. Lysine-specific demethylase 1 inhibitors protect cochlear spiral ganglion neurons against cisplatin-induced damage. Li A, He Y, Sun S, Cai C, Li H. Neuroreport 26 539-547 (2015)
  39. Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. Valente S, Rodriguez V, Mercurio C, Vianello P, Saponara B, Cirilli R, Ciossani G, Labella D, Marrocco B, Ruoppolo G, Botrugno OA, Dessanti P, Minucci S, Mattevi A, Varasi M, Mai A. ACS Med Chem Lett 6 173-177 (2015)
  40. Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Sun Q, Ding D, Liu X, Guo SW. Reprod Biol Endocrinol 14 17 (2016)
  41. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking. Zhou C, Kang D, Xu Y, Zhang L, Zha X. Chem Biol Drug Des 85 659-671 (2015)
  42. Inhibition of Lysine-Specific Demethylase-1 (LSD1/KDM1A) Promotes the Adipogenic Differentiation of hESCs Through H3K4 Methylation. Xiong Y, Wang E, Huang Y, Guo X, Yu Y, Du Q, Ding X, Sun Y. Stem Cell Rev Rep 12 298-304 (2016)
  43. Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells. Osada N, Kikuchi J, Umehara T, Sato S, Urabe M, Abe T, Hayashi N, Sugitani M, Hanazono Y, Furukawa Y. Oncotarget 9 6450-6462 (2018)
  44. Novel insights into histone modifiers in adipogenesis. Okuno Y, Inoue K, Imai Y. Adipocyte 2 285-288 (2013)
  45. Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML. Nicosia L, Boffo FL, Ceccacci E, Conforti F, Pallavicini I, Bedin F, Ravasio R, Massignani E, Somervaille TCP, Minucci S, Bonaldi T. Oncogene 41 878-894 (2022)
  46. Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer. Bouhaddou M, Yu LJ, Lunardi S, Stamatelos SK, Mack F, Gallo JM, Birtwistle MR, Walz AC. Clin Transl Sci 13 419-429 (2020)
  47. Screening assays for epigenetic targets using native histones as substrates. Hauser AT, Bissinger EM, Metzger E, Repenning A, Bauer UM, Mai A, Schüle R, Jung M. J Biomol Screen 17 18-26 (2012)
  48. Crystal Structure of LSD1 in Complex with 4-[5-(Piperidin-4-ylmethoxy)-2-(p-tolyl)pyridin-3-yl]benzonitrile. Niwa H, Sato S, Hashimoto T, Matsuno K, Umehara T. Molecules 23 E1538 (2018)
  49. Methods for Activity Analysis of the Proteins that Regulate Histone Methylation. Quinn AM, Simeonov A. Curr Chem Genomics 5 95-105 (2011)
  50. Synthesis, LSD1 Inhibitory Activity, and LSD1 Binding Model of Optically Pure Lysine-PCPA Conjugates. Itoh Y, Ogasawara D, Ota Y, Mizukami T, Suzuki T. Comput Struct Biotechnol J 9 e201402002 (2014)
  51. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation. Fioravanti R, Romanelli A, Mautone N, Di Bello E, Rovere A, Corinti D, Zwergel C, Valente S, Rotili D, Botrugno OA, Dessanti P, Vultaggio S, Vianello P, Cappa A, Binda C, Mattevi A, Minucci S, Mercurio C, Varasi M, Mai A. ChemMedChem 15 643-658 (2020)
  52. Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition. Abdel-Aziz AK, Pallavicini I, Ceccacci E, Meroni G, Saadeldin MK, Varasi M, Minucci S. Haematologica 105 2105-2117 (2020)
  53. Nitroreductase-Mediated Release of Inhibitors of Lysine-Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells. Herrlinger EM, Hau M, Redhaber DM, Greve G, Willmann D, Steimle S, Müller M, Lübbert M, Miething CC, Schüle R, Jung M. Chembiochem 21 2329-2347 (2020)
  54. Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1. Zhou C, Wu F, Lu L, Wei L, Pai E, Yao Y, Song Y. PLoS One 12 e0170301 (2017)
  55. Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer. Tang D, He J, Dai Y, Geng X, Leng Q, Jiang H, Sun R, Xu S. Cancer Gene Ther 29 543-557 (2022)
  56. Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity. Ourailidou ME, Lenoci A, Zwergel C, Rotili D, Mai A, Dekker FJ. Bioorg Med Chem 25 847-856 (2017)
  57. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A). Borrello MT, Schinor B, Bartels K, Benelkebir H, Pereira S, Al-Jamal WT, Douglas L, Duriez PJ, Packham G, Haufe G, Ganesan A. Bioorg Med Chem Lett 27 2099-2101 (2017)
  58. Parameters for Irreversible Inactivation of Monoamine Oxidase. Ramsay RR, Basile L, Maniquet A, Hagenow S, Pappalardo M, Saija MC, Bryant SD, Albreht A, Guccione S. Molecules 25 E5908 (2020)
  59. Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni. Coutinho Carneiro V, de Abreu da Silva IC, Amaral MS, Pereira ASA, Silveira GO, Pires DDS, Verjovski-Almeida S, Dekker FJ, Rotili D, Mai A, Lopes-Torres EJ, Robaa D, Sippl W, Pierce RJ, Borrello MT, Ganesan A, Lancelot J, Thiengo S, Fernandez MA, Vicentino ARR, Mourão MM, Coelho FS, Fantappié MR. PLoS Negl Trop Dis 14 e0008332 (2020)
  60. 3D-QSAR (CoMFA, CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyano-pyrimidine derivatives to explore the structure requirements of LSD1 inhibitors. Ding L, Wang ZZ, Sun XD, Yang J, Ma CY, Li W, Liu HM. Bioorg Med Chem Lett 27 3521-3528 (2017)
  61. Design and Synthesis of Benzene Homologues Tethered with 1,2,4-Triazole and 1,3,4-Thiadiazole Motifs Revealing Dual MCF-7/HepG2 Cytotoxic Activity with Prominent Selectivity via Histone Demethylase LSD1 Inhibitory Effect. Alsehli M, Aljuhani A, Ihmaid SK, El-Messery SM, Othman DIA, El-Sayed AAA, Ahmed HEA, Rezki N, Aouad MR. Int J Mol Sci 23 8796 (2022)
  62. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors. Xi J, Xu S, Wu L, Ma T, Liu R, Liu YC, Deng D, Gu Y, Zhou J, Lan F, Zha X. Bioorg Chem 72 182-189 (2017)
  63. Heterogeneous Antibody-Based Activity Assay for Lysine Specific Demethylase 1 (LSD1) on a Histone Peptide Substrate. Schmitt ML, Ladwein KI, Carlino L, Schulz-Fincke J, Willmann D, Metzger E, Schilcher P, Imhof A, Schüle R, Sippl W, Jung M. J Biomol Screen 19 973-978 (2014)
  64. A covalent adduct of MbtN, an acyl-ACP dehydrogenase from Mycobacterium tuberculosis, reveals an unusual acyl-binding pocket. Chai AF, Bulloch EM, Evans GL, Lott JS, Baker EN, Johnston JM. Acta Crystallogr D Biol Crystallogr 71 862-872 (2015)
  65. Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors. Gehling VS, McGrath JP, Duplessis M, Khanna A, Brucelle F, Vaswani RG, Côté A, Stuckey J, Watson V, Cummings RT, Balasubramanian S, Iyer P, Sawant P, Good AC, Albrecht BK, Harmange JC, Audia JE, Bellon SF, Trojer P, Levell JR. ACS Med Chem Lett 11 1213-1220 (2020)
  66. Structure-Activity Relationship and In Silico Evaluation of cis- and trans-PCPA-Derived Inhibitors of LSD1 and LSD2. Niwa H, Watanabe C, Sato S, Harada T, Watanabe H, Tabusa R, Fukasawa S, Shiobara A, Hashimoto T, Ohno O, Nakamura K, Tsuganezawa K, Tanaka A, Shirouzu M, Honma T, Matsuno K, Umehara T. ACS Med Chem Lett 13 1485-1492 (2022)
  67. Chemical modulation of Schistosoma mansoni lysine specific demethylase 1 (SmLSD1) induces wide-scale biological and epigenomic changes. Padalino G, Celatka CA, Rienhoff HY, Kalin JH, Cole PA, Lassalle D, Forde-Thomas J, Chalmers IW, Brancale A, Grunau C, Hoffmann KF. Wellcome Open Res 8 146 (2023)
  68. Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis. Sulejmani O, Grunewald L, Andersch L, Schwiebert S, Klaus A, Winkler A, Astrahantseff K, Eggert A, Henssen AG, Schulte JH, Anders K, Künkele A. Cancers (Basel) 13 5489 (2021)
  69. Insight into the binding mode of a novel LSD1 inhibitor by molecular docking and molecular dynamics simulations. Zhang X, Li M, Wang Y, Zhao Y. J Recept Signal Transduct Res 35 363-369 (2015)
  70. Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model. Trifirò P, Cappa A, Brambillasca S, Botrugno OA, Cera MR, Zuffo RD, Dessanti P, Meroni G, Thaler F, Villa M, Minucci S, Mercurio C, Varasi M, Vianello P. Future Med Chem 9 1161-1174 (2017)
  71. Inhibition of FAD-dependent lysine-specific demethylases by chiral polyamine analogues. Umezawa N, Tsuji K, Sato S, Kikuchi M, Watanabe H, Horai Y, Yamaguchi M, Hisamatsu Y, Umehara T, Higuchi T. RSC Adv 8 36895-36902 (2018)
  72. Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity. Fioravanti R, Rodriguez V, Caroli J, Chianese U, Benedetti R, Di Bello E, Noce B, Zwergel C, Corinti D, Viña D, Altucci L, Mattevi A, Valente S, Mai A. J Enzyme Inhib Med Chem 37 973-985 (2022)
  73. Lysine demethylase LSD1 is associated with stemness in EBV-positive B cell lymphoma. Kim JH, Park C, Kim WS. Sci Rep 14 6764 (2024)
  74. Novel 17-bp Deletion in KDM1B Gene is Significantly Associated with Testis Weight in Male Piglet. Cui Y, Hu T, Chen R, Yu S, Dong W, Lv X, Pan C. Anim Biotechnol 29 252-258 (2018)
  75. [Antiproliferative effect of silencing LSD1 gene on Jurkat cell line and its mechanism]. Han S, Huang Y, Zheng R. Zhonghua Xue Ye Xue Za Zhi 37 56-60 (2016)


Quick links